A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

Inclusion Criteria: * Male or female aged 18 years or older * Best-corrected visual acuity (BCVA) of 65 letters read or greater (Snellen equivalent of 20/50 or better) in the study eye * HbA1c ≤ 12%, as assessed by the central laboratory * Moderate to very severe NPDR as per ETDRS Severity Scale, based on 7 standard field stereo colour fundus photograph * Central subfield thickness of ≤ 340µm on Spectralis SD-OCT or ≤ 320µm on non-Spectralis SD OCT in the study eye, with or without mild centre-involved diabetic macular oedema * No evidence of total PVD in the study eye * Written informed consent obtained from the subject prior to screening procedures Exclusion Criteria: * History of or current ocular condition in the study eye that may interfere with the assessment of the progression to PDR * Presence of epiretinal membrane in the study eye * Presence of foveal ischemia in the study eye * Presence of pre-retinal or vitreous haemorrhage in the study eye * Presence of iris or angle neovascularisation in the study eye * Any active ocular / intraocular infection or inflammation in either eye * Aphakic study eye * Uncontrolled hypertension in the opinion of the Investigator * Pseudoexfoliation, Marfan's syndrome, phacodonesis or any other finding in the Investigator's opinion suggesting lens / zonular instability